Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07746180 Obinutuzumab β Granulomatosis With Polyangiitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07746180 clinical trial report covering Obinutuzumab β, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744724 Polatuzumab Vedotin-Piiq Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744724 clinical trial report covering Polatuzumab Vedotin-Piiq, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07745361 Apalutamide Castration-Resistant Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07745361 clinical trial report covering Apalutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07745426 Diosmin Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07745426 clinical trial report covering Diosmin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07745725 TollB-001 Scleroderma, Diffuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07745725 clinical trial report covering TollB-001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744932 Toripalimab Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744932 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07745257 Anlotinib Dihydrochloride Metastatic HER2-Negative Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07745257 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744750 Pirtobrutinib Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744750 clinical trial report covering Pirtobrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744919 Emapalumab-LZSG Hepatic Encephalopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744919 clinical trial report covering Emapalumab-LZSG, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07743632 Cyclophosphamide Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743632 clinical trial report covering Cyclophosphamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744126 Telisotuzumab adizutecan Squamous cell carcinoma of head and neck metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744126 clinical trial report covering Telisotuzumab adizutecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07743554 Avutometinib Neurofibrosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743554 clinical trial report covering Avutometinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.